We demonstrated a significant increase in PAR1 expression in HPSC subgroups, particularly in association with PAR1 inhibition, which altered the inflammatory state of MPN cells and mitigated the aberrant activation associated with MPN pathogenesis. This evidence concerns the gene F2R and myeloproliferative neoplasm.